Changes to the Ontario Drug Benefit (ODB) Formulary effective February 28, 2018

New Single Source Drugs
Metoject Subcutaneous (methotrexate sodium) 17.5mg/0.35mL, 20mg/0.4mL, 22.5mg/0.45mL, 25mg/0.5mL Inj Sol – Pref Syr (MDX)
Changes to Limited Use (LU) Criteria

Aclasta (zoledronic acid) (NOV) and Generics (DRR, TAR, TEV) 5mg/100mL Inj Sol – 100mL Pk (Preservative-Free)

New LU code 523 (treatment of osteoporosis in males) and revised LU criteria


Full summary of changes available on the Ministry’s website: